David T. Rubin to Protein Kinase Inhibitors
This is a "connection" page, showing publications David T. Rubin has written about Protein Kinase Inhibitors.
Connection Strength
1.832
-
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
Score: 0.568
-
Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018 11; 35(11):1746-1762.
Score: 0.488
-
The use of tofacitinib in the treatment of inflammatory bowel disease. Immunotherapy. 2018 08; 10(10):837-849.
Score: 0.471
-
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis. 2021 Jul 05; 15(7):1130-1141.
Score: 0.147
-
The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am. 2019 Jul; 29(3):405-419.
Score: 0.126
-
Renin-angiotensin system promotes colonic inflammation by inducing TH17 activation via JAK2/STAT pathway. Am J Physiol Gastrointest Liver Physiol. 2019 06 01; 316(6):G774-G784.
Score: 0.032